Alexander E. Drilon, MD

Alexander Drilon, MD, discusses what community oncologists should know about testing for  NTRK gene fusions in patients with solid tumors.

Alexander Drilon, MD, discusses the differences in how TRK fusions manifest in older patients vs younger patients.

Alexander E. Drilon, MD, discusses the next steps for LOXO-292 in 2 subsets of patients: those with RET fusion-positive cancers and <em>RET</em>-mutant medullary thyroid cancers.

Alexander E. Drilon, MD, discusses the prevalence of <em>RET</em> fusions and mutations in patients with cancer, including lung and thyroid cancers.